The mTOR inhibitors remain the first-line drug for LAM in both men and women.[51] Based on the current findings, renal hemangioma volume was reduced in 2 patients with TSC-LAM who were treated with sirolimus. The gene discussed is MTOR; the disease is lymphangioleiomyomatosis.